Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. (Nasdaq: NAUT) is a development-stage life sciences company building a proprietary single-molecule protein analysis platform aimed at transforming proteomics research. The company entered the public markets through a business combination with Arya Sciences Acquisition Corp III, a blank-check vehicle sponsored by Perceptive Advisors, with the SPAC having completed its IPO in 2020 and the merger closing in June 2021. The 10-Q filed in May 2021 reflects Nautilus at an early commercial stage, with its core protein sequencing technology still advancing toward full commercialization. Sign up on SpacDesk for complete filing data, SPAC deal analytics, and sponsor tracking on NAUT and the broader SPAC universe.